|16 January, 2020

Ground-breaking scalp cooling treatment that minimises hair loss in Middle Eastern chemo patients showcased at Arab Heath 2020

Chemotherapy-induced hair loss is widely recognised as one of the most traumatic side effects associated with cancer treatment

Ground-breaking scalp cooling treatment that minimises hair loss in Middle Eastern chemo patients showcased at Arab Heath 2020

A ground-breaking British technology that prevents Middle Eastern cancer patients from losing their hair during chemotherapy will be showcased at Arab Health 2020.

Scalp cooling expert, Paxman is exhibiting the next generation Paxman Scalp Cooling System (PSCS) at the exhibition, which has been designed to help men and women keep their hair and retain a feeling of normality during treatment for cancer.

Chemotherapy-induced hair loss is widely recognised as one of the most traumatic side effects associated with cancer treatment. For many patients hair loss can have a detrimental impact on their sense of identity – a visible sign that they have cancer. In fact 8% of female cancer patients say they would decline treatment for fear of hair loss, which remains a well-known side effect of many chemotherapy regimens, affecting approximately 65% of individuals undergoing treatment.

Today scalp cooling also known as the 'cold cap' is proven to be effective in combatting hair loss and is a well-accepted treatment throughout the world. It can be used with all solid tumour cancers.

The Paxman Scalp Cooling System is used extensively throughout the UK in NHS hospitals and private clinics and is well established in many other countries across 38 US states Europe and the Middle East – including the UAE, Kuwait, Jordan, Lebanon, Iran, and Turkey. Extending its reach across the Middle East, Paxman has just appointed new distribution partners in Saudi Arabia and Israel and will begin selling scalp cooling systems to hospitals in 2020.

The British manufacturer will be taking advantage of its presence at Arab Health to strengthen its links across the Middle East – where its pioneering systems are already installed in state-of-the-art healthcare facilities across the region. This includes, in the UAE, Mediclinic City Hospital – South Africa’s leading private hospital group – in the world-famous Dubai Healthcare City; and more recently the multi-speciality hospital American Hospital Dubai.

The company has plans to expand to Israel and Saudi Arabia in 2020 and are looking to create new partnerships at Arab Health to further develop their reach to key markets including Egypt and Bahrain as well as other parts of the world. 

Richard Paxman, CEO at Paxman said: “We are delighted to be able to offer scalp cooling to Middle Eastern patients and are keen to find new partners from across the region. Scalp cooling can result in a high level of retention or in some cases completely preserve the hair for patients undergoing chemotherapy – a chance for them to retain their sense of self while encouraging a positive attitude towards treatment.”

 “As a company we want to empower patients, professionals and other people all over the world – especially in places where hair loss remains a stigma. We want to help improve peoples’ self-confidence in facing what can be one of the most distressing side effects of chemotherapy – and give them a choice.”

The Arab Health Exhibition & Congress is taking place from 27 January – 30 January 2020. Throughout the exhibition the Paxman Scalp Cooling System will be located in hall 2 stand D12. 

To find out more about scalp cooling visit www.paxmanscalpcooling.com

© Press Release 2020

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.

More From Press Releases